Arthritis refers to a collection of diseases that affect the joints, causing pain and stiffness. There are more than one hundred types of arthritis which can be broadly categorised as either inflammatory or non-inflammatory.
Non-inflammatory arthritis includes osteoarthritis, the most common form of arthritis. Osteoarthritis involves degeneration of the articular cartilage that protects the ends of the bones and is a leading cause of disability around the world.
Inflammatory arthritis may arise as the result of an autoimmune or autoinflammatory response. Examples include rheumatoid arthritis and spondyloarthropathies such as ankylosing spondylitis and psoriatic arthritis.
There is no known cure for arthritis, so current treatment strategies focus on providing effective palliation and slowing disease progression. Treatment may vary considerably depending upon type and severity.
To find out more about osteoarthritis, visit our dedicated Learning Zone, which contains further information on the treatment strategies, medications and relevant guidelines that are available to facilitate the successful management of this condition.
Related news and insights
The Janssen Pharmaceutical Companies of Johnson & Johnson announced a Network Meta-Analysis (NMA) comparing first-in-class interleukin (IL)-23 inhibitor Tremfya (guselkumab) to all advanced therapies approved for active psoriatic arthritis (PsA using data from 33 Phase III randomized clinical trials (RCTs).
UCB has announced positive top-line results from the Phase III BE COMPLETE study which evaluated the efficacy and safety of Bimzelx (bimekizumab) in the treatment of adults with active psoriatic arthritis, who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-?) therapy.
AbbVie has announced that the FDA has approved Rinvoq (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.